While AbbVie’s ADC approval expands oncology options, CMS finalized a rule aimed at simplifying payer-provider disputes under the No Surprises Act by streamlining arbitration. Provider groups largely welcomed the changes, though some leaders argued additional improvements are needed for transparency and to prevent alleged misuse. The policy is separate from drug development, but it can affect coverage economics and reimbursement planning—an operational reality for companies navigating launch cycles. For biotech leaders, these moves underscore how reimbursement rules and clinical innovation are evolving in parallel, with concrete implications for market access and revenue forecasts.